JIG投稿手続き Step by step 出版前チェック(pre-publication check)






実際の投稿画面 SUBMIT TO THIS GATEWAY



黄色の→で示したボタンをクリック





投稿前に確認しないといけない事項を読み SUBMIT A NEW ARTICLEをクリック

About I

How it W

For Revi

Our Advi

Policies

Glossary

FAQs

Contact

English 日本語





Home » Gateways » Japan Institutional Gateway » Submit Your Research

Submit your Research

Articles

Articles are published rapidly as soon as they are accepted, after passing a series of prepublication checks to assess originality, readability, author eligibility, and compliance with F1000Research's policies and ethical guidelines. Peer review by invited experts, suggested by the authors, takes place openly after publication. An article remains published regardless of the reviewers' reports. Articles that pass peer review are indexed in Scopus, PubMed and other bibliographic databases. All published articles are included in Google Scholar, irrespective of peer review status.

GATEWAY HOMEPAGE ABOUT THIS GATEWAY BROWSE HOW TO PUBLISH/掲載の仕方 V ABOUT/その他の情報 V

Authors are encouraged to publish revised versions o model.

See the <u>Article Guidelines</u> formation about submitting different article types. Track your submissions via <u>My</u>

Research.
F1000Research only offe
December 2019). If you wo

slides then please contact

SUBMIT A NEW ARTICLE

blication of scholarly posters and slides within gateways and collections (as of xe to create a collection or gateway for the hosting of your community's posters and

ond openly to the peer review reports, which are published with the article, and can

article at no further cost, if they wish. Read more about F1000Research's peer review

>> SUBMIT A NEW VERSION


>> COMPLETE A DRAFT

Before you submit an article, please ensure that:

★ SUBMIT

- The work is original. The manuscript (or substantial parts of it) must not have been published previously, or be under consideration or review by another journal. Manuscripts that were previously posted on a preprint server such as ArXiv or BioRxiv are welcome.
- At least one author is a qualified researcher (according to F1000Research's <u>authorship criteria</u>) and has made a key contribution to the article.
- 3. The reported study meets all applicable **research and publication standards**. We strongly recommend that you consult our **editorial policies** for more detail on reporting quidelines and ethical requirements.
- 4. All methodological details and relevant data are made available to allow others to replicate the study, and that the manuscript adheres to appropriate reporting guidelines and community standards. For more detail, please see our policies and <u>Data preparation guidelines</u>.
- All authors have understood F1000Research's policies for article publication and its <u>author-led publishing</u> <u>model</u>, which requires authors to actively suggest suitable peer reviewers for their article until at least 2 reports have been received.
- 6. Your manuscript includes full author and affiliation information, and a conflict of interest statement.
- You agree to pay any <u>processing charges</u> applicable to this submission. Following submission, we will ask you
 for the name and email address of the payer, the name of their institution and the country in which they are
 based. If based in an <u>EU member country</u>, we will also require a VAT registration number.







FICCO	Research					Search	Q
BROWSE	GATEWAYS & CO.	NS	HOW TO PUBLISH +	ABOUT ~	BLOG		MY RESEARCH ~
<u>Home</u> » Sign Ir	n						
	Sign in Regis	ter					
	Email Address					native method to sign	
	Password			20		you agree to F1000Researd al Terms & Conditions	chis
	Forgotten your pass	word?		OR	G	Log In with Google	
	Remember me		SIGN IN		f Log	g In with Facebook	



氏名など必要項目を入力



Any queries (or problems, please contact us.
- First Name * -	·
- Last Name* -	O CHILDRESS
– Institution * —	
Not Applic	able
he name and t Vhere applical anguage and i	n English. Do not paste in the name. If the
he name and t Where applical anguage and i name does not	then select the correct name from the list. In the name will appear in both the origina In English. Do not paste in the name. If the In appear in the drop-down list, we will displa In you have entered.
he name and t Where applical anguage and i name does not he informatior	then select the correct name from the list. In the name will appear in both the origina In English. Do not paste in the name. If the In appear in the drop-down list, we will displa In you have entered.

I would like to receive:

▼ F1000Research content alerts

You can customise the content of this alert via your My pages.

The Monthly Update email, plus other occasional announcements from F1000 Research Ltd and the Taylor & Francis Group

Note: In accordance with our privacy policy, we will not share your personal information with third parties.

✓ I accept the Terms and Conditions



REGISTER


コンテンツアラートや 情報を受け取りたい場 合はこちらのボックス をクリック。

Term and Conditions 確認したらクリック



Email アドレスに認証メールが送信される







認証メールを受信したら該当リンクから 認証手続きを行う



Please validate your email address D Inbox x

info@f1000.com via amazonses.com

to me 🔻

Dear TOMOKO,

To complete your registration with F1000Research, please validate your email address by clicking:

https://f1000research.com/register/validation/email?token=1142582&originalPath=/author/submit/new&channel=japan-institutional-gateway

If you have any questions or comments please contact our Customer Service team by email at info@f1000.com.

Best regards,

The F1000Research team F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notifications and should not be used by anyone who is not the original intended recipient. copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Resear any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited by means of e-mail communication. England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.




ORCID IDと連動させます ORCID IDをお持ちでない場合は登録下さい。

BROWSE GATEWAYS & COLLECTIONS HOW TO PUBLISH - ABOUT - BLOG



SUBMIT YOUR RESEARCH

MY RESEARCH - SIGN OUT



F1000Research

Return to the page you were on

You now have access to:

Search

- Submit articles and track peer review progress
- · Submit posters and slides for immediate publication
- Submit an invited peer review report
- Comment on articles, posters and slides, and article peer review reports
- Track articles and create tailored alerts

Any queries regarding submission, requests to review, or using the site, please email us.

Return to the page you were on.



ORCID IDの承認 F1000と連動させます



Authorize access

You are currently signed in as:

Tomoko Yamanojo-Childress

https://orcid.org/0000-0001-9978-0155

Sign out



has asked for the following access to your ORCID record:



ල Add/update your research activities (works, affiliations, etc)

Authorize access

Deny access

If authorized, this organization will have access to your ORCID record, as outlined above and described in further detail in ORCID's privacy policy.

You can manage access permissions for this and other Trusted Organizations in your account settings.



f1000research.com/orcid/oauthcallback/works/create/user?userId=1142582&code=IQZU... —

f1000research.com/orcid/oauthcallback/works/create/user?userId=1142582&code=IQZUQr 1000Research

Your (D) ORCID profile

We were unable to connect your ORCID iD - authorization failed.

F1000Research supports the use of ORCID iDs where possible. If you want to submit an article to F1000Research, you must connect to an ORCID iD.

What is ORCID?

ORCID (Open Researcher and Contributor ID) is an identifier for individuals to use with their name as they engage in research, scholarship, and innovation activities. It provides a persistent identifier for humans, similar to that created for content-related entities on digital networks by digital object identifiers (DOIs).

Why is ORCID good for you?

- 1. ORCID allows identification beyond names. Globally, names can be very common, they can change, they can be transliterated into other alphabets and so reliably linking researchers with their research and organizations can be difficult - this is solved through a unique
- 2. An ORCID iD also allows you to keep a constantly updated digital curriculum vitae. Individuals decide to register, which research activities to connect to their ID, which organizations to allow access, what information to make publicly available, what to share with trusted parties, and what to keep private. Individuals can control their profiles and can change these settings and permissions at any time.


Press OK to close this window. Contact us.



登録完了画面になる









登録完了したら SUBMIT A NEW ARTICLEをクリック



FICOResearch

Search

Q SUBMIT YOUR RESEARCH

BROWSE GATEWAYS & COLLECTIONS HOW TO PUBLISH V ABOUT V BLOG

MY RESEARCH V SIGN OUT

Home » Submit Your Research

How to Publish

Submit your Research

My Submissions

Article Guidelines

Article Guidelines (New Versions)

Data Guidelines

Posters and Slides Guidelines

Document Guidelines

Article Processing Charges

Peer Review

The Peer Review Process

The Editorial Team's Role

Understanding Peer Review Reports and Statuses

Revising and Responding to Reviewers

Finding Article Reviewers

The Peer Review Process Articles are published rapidly as soon as they are accepted, after passing a series of prepublication checks to assess originality, readability, author eligibility, and compliance with F1000Research's policies and ethical guidelines. Peer review by invited experts, suggested by the authors, takes place openly after publication. An article remains published regardless of the reviewers' reports. Articles that pass peer review are indexed in Scopus, PubMed and <a href="https://doi.org/10.1007/journalists/bub

Authors are encouraged to respond openly to the peer review reports, which are published with the article, and can publish revised versions of their article at no further cost, if they wish. Read more about F1000Research's

See the <u>Article Guidelines</u> for information submitting different article types. Track your submissions via My Research

F1000Research only offers the pub and collections (as of December 20 the hosting of your community's pc and slides then please contact us.

SUBMIT A NEW ARTICLE

>> SUBMIT A NEW VERSION >> COMPLETE A DRAFT

Before you submit an article, please ensure that:

- The work is original. The manuscript (or substantial parts of it) must not have been published previously, or be under consideration or review by another journal. Manuscripts that were previously posted on a preprint server such as ArXiv or BioRxiv are welcome.
- At least one author is a qualified researcher (according to F1000Research's authorship criteria) and has made a key contribution to the article.
- The reported study meets all applicable research and publication standards. We strongly recommend that you consult our <u>editorial policies</u> for more detail on reporting guidelines and ethical requirements.

About F1000Research

How it Works
For Reviewers
Our Advisors
Policies
Glossary
FAQs
Contact



ORCID IDが紐づけされている事を確認 Article typeから入力していく



1000Research		Search	Q 1 SUBMIT YOUR RI	ESEARCH
OWSE GATEWAYS & COLLEC	CTIONS HOW TO PUBLISH ~	ABOUT ~ BLOG	MY RESEARCH ~	SIGN OUT
ne » Submit				
ubmit Your Manusc	ript		★ indicates a required	d field
Your ORCID iD 10	https://orcid.org/0000-0	<u>001-9978-0155</u>		0
About the Article				
Article Type *	Research Article	Case Report	Systematic Review	
Guidance about choosing an article	O Brief Report	Clinical Practice Article	Opinion Article	
<u>type</u> .	O Data Note	O Software Tool Article	Ocorrespondence	
	Genome Note	Method Article	○ Editorial	
	O Policy Brief Case Study	Study Protocol Review		
	Case study	0		
Article Title *	Case study			
Article Title *	Case study		[I X ₂ :	ײ
Article Title *	Case study		[] X ₂ :	ײ
Article Title * Abstract *	Case study		[[X _a] :	ײ
	Case study		I X ₂	X²
	Words: 0/300		$I \times_2$:	ײ



著者情報入力 著者の貢献度も選択



Authors *

Please list all author names in the form that they should appear on the final publication. You can reorder authors using the arrows icon.

Note that anyone not listed here, for example those within a collective, will not be recognised as authors in indexing sites such as PubMed and Scopus.

AUTHORS	AFFILIATIONS SQ UNLINK ALL + ADD
TOMOKO YAMANOJO CHILDRESS	Sophia College for Women X
	Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name if the name does not appear in the dropdown list, we will display the information you have entered.
	Department
	Mumbai
	Maharashtra
	Zip/Postcode
	India

所属機関

Please list all affiliations in the form

PLEASE NOTE Once you start linking authors to affiliations, you will not be able to delete or reorder the authors or affiliations. If you need to delete or reorder, please select UNLINK ALL and

You do not need to add affiliations for

Click the
on the right for more information.




Affiliations *

Please list all affiliations in the form that they should appear on the final publication.

PLEASE NOTE Once you start linking authors to affiliations, you will not be able to delete or reorder the authors or affiliations. If you need to delete or reorder, please select UNLINK ALL and start again.

You do not need to add affiliations for consortia/collectives.

Click the
 on the right for more information.



AUTHORS	AFFILIATIONS	ଷ୍ଟ UNLINK ALL	+ ADD
•		血	
You have not added any authors		have not added ny affiliations	




氏名



共著者











Affiliations *

Please list all affiliations in the form that they should appear on the final publication.

PLEASE NOTE Once you start linking authors to affiliations, you will not be able to delete or reorder the authors or affiliations. If you need to delete or reorder, please select UNLINK ALL and start again.

You do not need to add affiliations for consortia/collectives.

Click the **1** on the right for more information.


AUTHORS	AFFILIATIONS	8⊘ UNLINK ALL	+ ADD	•
Tomoko Yamanojo Childress (1)	1. Utsunomiya Univers Prefecture, Japan	sity, Utsunomiya, Tochigi ,	i 1	

Please ensure that you have selected at least one affiliation per author (does not apply to consortia/collectives). Please watch the explanatory video.



Funding情報の入力 画面の例は科研費の入力例











Files				
Upload manuscript * DOC, DOCX or RTF. For LaTeX, upload a ZIP file of the project that includes the PDF.		СН	DOSE FILE	
Upload figure file(s)		СН	DOSE FILE	
Upload covering letter		СН	DOSE FILE	







Data

UNDERLYING DATA

All articles that report original results must include details of how the raw underlying data can be accessed by peer reviewers and readers (when it is safe and ethically permissible to do so). You must upload the data to a data repository and make it public before your article is submitted.

EXTENDED DATA

Additional materials that support the key claims but are not absolutely required to follow the study design and analysis of the results, e.g. questionnaires or supplementary figures, should also be uploaded to a stable and recognised open repository as extended data.

REPORTING GUIDELINE CHECKLIST

Reporting guidelines checklists should be provided for the following study types and uploaded to a stable and recognised open repository: clinical trials (CONSORT); clinical trial protocols (SPIRIT); systematic reviews (PRISMA); systematic review protocols (PRISMA-P); and in vivo experiments (ARRIVE). Guideline checklists can be found on the Equator Guidelines page. If submitting a reporting guideline checklist, please select "Yes: some or all of my data have been shared" in the form and then select "Extended" under "Select type of data".



Have you shared your data openly in a data repository? *	
Guidance on preparing and depositing data	

Yes: some or all of my data have been shared

No: none of my data can be shared, or I did not use data





データをシェアできない、もしくは データない論文の場合でNoを選択した時の画面

Please specify the reason(s) for not being able to provide details about the data:

No data associated with this article

This article is a method, study protocol or clinical practice article, or data is not relevant to the research method, therefore no data are associated with it.

test										
Words: 1/500	В	I	<u>U</u>	ײ	ײ	$\underline{\mathbb{T}}_{\times}$	1= 2=	0 = 0 =	e	€ ₹

データが シェアでき ない理由を 選択

☐ Ethical or security consideration

Please include a description of the restrictions on the data and all necessary information required for a reader or reviewer to apply for access to the data and the conditions under which access will be granted.

■ Data protection issue

Please include a description of the restrictions on the data; what, if anything, the Institutional Review Board or equivalent said about data sharing; and, where applicable, all necessary information required for a reader or reviewer to apply for access to the data and the conditions under which access will be granted.

☐ Too large

Please include the size of the dataset, a description of what it contains and all necessary information required for a reader or reviewer to access the data, with a description of this process.

Provided by a third party

Please include all necessary information required for a reader or reviewer to access the data by the same means as the authors, as well as any publicly available data that is representative of the analysed dataset that can be used to apply the methodology described in the article.



* Ζ I confirm that I understand that failure to share the data underlying my study without a valid reason is likely to result in my article being rejected.



APC支払いに関する同意 Article typeによってAPC金額が 3 Categoryに分類されます。



Payment

Articles accepted for publication in F1000Research are subject to an Article Processing Charge (APC) - a full explanation of the prices and transparency breakdown is available here. I understand that the authors are responsible for the payment of the APC upon acceptance of the article, regardless of the peer review outcome, unless the article has been confirmed to be eligible for a waiver.

Do you think you might be eligible for a discount or waiver?



F1000Researchに掲載が認められた論文には、論文出版料(APC)が 課せられます。価格と透明性の内訳についての詳しい説明は、こちら→ をご覧ください。

私は(論文が免除(Waiver)の対象となることが確認された場合を除き) 査読の 結果にかかわらず論文が受理された時点で著者がAPCの支払いに責任を 負うことを理解しています。

※F1000でいう論文の受理とは、出版前チェックを通過したVersion1の 出版受理の事です。(査読はVersion1出版後に始まります)

Category A

Includes: Data Notes.

Correspondence. Genome Notes, Case Studies

\$910°

Category B

Includes:

Study Protocols. Registered Reports, Software Tool Articles, Brief Reports, Policy Briefs

\$1,150°

Category C

Includes:

Research Articles, Method Articles, Antibody Validation Articles, Reviews, Systematic Reviews, Clinical Practice Articles, Case Reports, Opinion Articles

\$1,595





Conflict of Interestの申告 Gatewayにチェックを入れる 編集チームへのコメントを入力(何かあれば)



Do you have any competing interests to disclose? *	○ Yes	0
Submit to a gateway or a collection	Gateways provide personalized portals to collate publications from scholarly societies, funders, institutions, and communities working in specific research disciplines. Collections are compilations of related research outputs that are curated around one specific theme. If you are interested in contributing, please select an option below - currently you can only select either one gateway or one collection. If you wish your article to be considered for others, please let us know via the Notes to editorial team below. © Gateways Ocollections	
	Choose gateway ~	
Notes to editorial team	Enter any additional information for the editorial team here.	



License Agreements Creative Commons CC BY License使用の承諾





License Agreements

F1000Research publishes articles under the Creative Commons license. Please tick the boxes below to confirm your acceptance of the F1000 Research Limited Terms and Conditions and the terms of the following Creative Commons licenses in connection with the article being submitted ("the Article").

0

- ✓ I accept the F1000 Research Ltd <u>Terms and Conditions</u> for publication
- ✓ I and my co-authors (if any) authorize the use of the Article in accordance with the Creative Commons CC BY license
- For NIH Employees only: I am an employee of the NIH and as a result the above license is subject to the terms of the NIH

 Publishing Agreement and Manuscript Cover Sheet

CCライセンスとはインターネット時代のための新しい著作権ルールで、作品を公開する作者が「この条件を守れば私の作品を自由に使って構いません。」という意思表示をするためのツールです。CCライセンスを利用することで、作者は著作権を保持したまま作品を自由に流通させることができ、受け手はライセンス条件の範囲内で再配布やリミックスなどをすることができます。https://creativecommons.jp/licenses/



各宣言(ステートメント)を確認した後 内容を理解してから問題がなければチェックを入れ SUBMITをクリックして投稿完了



Declarations

- ✓ I confirm that I and my co-authors are the authors of the Article.
- ✓ I confirm that my co-authors have agreed to the submission of the Article and the Data and have authorized me to act as their agent in relation to its submission.
- ✓ I confirm that my co-authors and I have all necessary rights and have obtained all necessary permissions and consents to grant the rights granted to the Article in the License section above.
- ✓ I confirm that this Article is not currently under consideration or review by another publisher, elsewhere.
- ✓ If applicable: I confirm that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. (If this is the case, this statement will be added to the Grant information section of your manuscript at publication.)

CANCEL

SAVE AS DRAFT

SUBMIT



システムから投稿完了のメールを 受信したかご確認下さい。





editorial@f1000research.com via amazonses.com

to me *



:

Dear TOMOKO

Thank you for submitting your manuscript:

test

YAMANOJO CHILDRESS T

Funders: no grant funding was stated during submission.

Article Processing Charges (APCs) on F1000Research are based on article type. Charges are payable once the article has been accepted for publication. A full explanation of the price transparency breakdown for the article type categories is available here.

WHAT WE DO NEXT

Before accepting your article: we will check content suitability, readability and manuscript format; adherence to ethical standards for the type of study; that the underlying data have been supplied (where appropriate); and that there is sufficient detail to enable others to replicate the study (if applicable).

Before publishing your article: if we accept your article, we will be in touch as soon as possible with any issues that need addressing. You will then receive a final proof of your article for approval, prior to publication.

WHAT YOU NEED TO DO NEXT

Before doing anything else, we need you to suggest at least 5 suitable reviewers to peer review your manuscript following publication (in accordance with our <u>publishing model</u>), should it be accepted. We ask that authors do not contact reviewers directly about the peer review process. We will need your reviewer suggestions before we can publish the article so we recommend identifying them now via your <u>Suggest Reviewers</u> page for this article. You can also access this page via the article's record at <u>My</u>. Research >> <u>Submissions</u>.

Please quote the article number 140567 in any correspondence.

Kind regards

The F1000Research Team

Press releasing articles: Please avoid promoting articles in the media until the article has passed the <u>open peer review process</u>. Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SWIP 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER153936-A (end code)



F1000編集者が出版前チェックを行っている間に 査読者を探して入力しましょう。



WHAT YOU NEED TO DO NEXT

Before doing anything else, we need you to suggest at least 5 suitable reviewers to peer review your manuscript following publication (in accordance with our <u>publishing model</u>), should it be accepted. We ask that authors do not contact reviewers directly about the peer review process. We will need your reviewer suggestions before we can publish the article so we recommend identifying them now via your <u>Suggest Reviewers</u> page for this article. You can also access this page via the article's record at <u>My Research >> Submissions</u>.

Please quote the article number 140567 in any correspondence.

Kind regards

The F1000Research Team



メール内のSuggest Reviewersをクリックすると 査読者候補を入力する画面になります。



WHAT YOU NEED TO DO NEXT


Before doing anything else, we need you to your manuscript following publication (it accepted. We ask that authors do not will need your reviewer suggestions between each publish the article so we recommend identifying them now via your Suggest Reviewers page for this article. You can also access this page via the article's record at My Research >> Submissions.

Please quote the article number 140567 in any correspondence.

Kind regards

The F1000Research Team

論文の内容からReviewer Finder toolが 独自のアルゴリズムで査読者候補を出して くることがあるので適宜ご活用下さい。





出版前チェックとは?



F1000では査読前に論文が出版されます。機関レポジトリに代表されるプレプリントと違うのは、Version1出版前に出版前チェックがあることです。

- 1) 投稿後, 初回チェックを行い、論文の不備があれば著者にF1000 Editorよりご連絡します。
- 2) Editorから連絡があったら著者は速やかに指摘された点を修正し再度投稿してください。
- 3) F1000ポリシーとガイドラインを満たしているかも確認されます。
- 4) Accept (通過) された論文は、出版準備のため制作段階に移されます。







著者の必要要件 ICMJE; CRediT



言語(英語) レベルチェック



論文の基礎データ アクセス可能か データに関するステート メントがあるか



倫理規定 倫理委員会の承認 患者のインフォームドコ ンセントなど



実際のチェック項目 (データ以外)



E				
Front Matter	Declarations	Back Matter		
ロ タイトル	□ 必要な許諾を得ているか	□ 参考文献		
□ 著者リスト	□ Conflict of Interests	bibliography		
□ 所属機関	利益相反	□ 図 Figure		
□ Abstract	□ 資金提供	□ 表 Table		
Abstract	□ =計式文 A alemanda de e constante	ロ サプルメンタリーAppendices/		
(字数制限を守っているか等)	□ 謝辞Acknowledgements	supplementary files		

https://f1000research.com/for-authors/article-guidelines

Keywords

日本語論文(人文社会科学のみ)のガイドライン

https://f1000 research.com/gateways/japan-institutional-gateway/for-authors/article-guidelines? alternate Language View=true

著者は、JIG著者資格基準を満たし、編集チームからの連絡を受けるための個人メールアドレス(可能であれば機関名)を提供すること。

実際のチェック項目(データ以外)



- 著者資格: JIGでは所属機関がJIG Affiliate(協賛機関)であること
- ・ 論文のオリジナリティ: 剽窃チェック, iThenticate, used to check articles
 - ✓ 論文は著者自身の言葉で書かれたものであること
 - ✓ 大量の盗用箇所がある論文は却下される可能性が高いのですが、一概にはいえません。内容を注意深くEditorが確認します。転載、引 用は正しく行うこと。
 - ✓ 著者自身の過去の論文との軽度の重複など、深刻な重複でなければ該当部分を書き直しいただくことで対応いただきます。
 - **✓ 言語チェック:原稿に軽い文法のミス等についてCopyeditingを行います。大幅なCopyeditingは行いません。**
 - √ 報告:方法論(メソッド)は、他の人が再現できるものであるべきでReportingガイドラインに従うことが重要です。必ずガイドラインを参照下さい
 - ✓ 倫理規定:論文には倫理委員会の承認(人および動物実験)や必要な同意(人に関する実験のインフォームドコンセント等)が取得され論文内に記述があること
 - ✓ 必要な倫理関連の承認/患者の同意等が得られていない場合、または適用されない場合は、その事実を詳しく説明する必要があります
 - ※宣言すべき事項がないことも宣言しなくてはいけません







倫理関連で該当する場合、必要な倫理に関する宣言を論文内に挿入する

- ヒトまたは動物を対象とするすべての研究は、実施前に各研究機関の倫理的な承認を得なければならない(日本においては各機関の倫理委員会の承認、承認番号、承認された通知がある)
- 論文投稿の際には、機関名、審査委員会名、許可番号など、この承認の詳細を提供する必要があります。

RESEARCH ARTICLE

REVISED Perceptions of Surrogacy Within the Socio-Cultural Context of Nigeria [version 2; peer review: 2

approved with reservations]

Previously titled: A qualitative investigation of surrogacy as a panacea for infertility in Nigeria

機関から承認された旨の宣言と承認番号など記載

Ethical considerations

This study was approved by the University of KwaZulu-Natal ethical clearance Committee (Protocol number: HSS/0705/017M) after due consultation and the gatekeepers' consent letters were provided by Ekiti State Teaching Hospital, Ado-Ekiti, Ekiti- State and Oyedeji Ayodele and Co, Abuja Nigeria.

Open Peer Review 公開査読





公開査読とは何が公開されるのでしょう



公開された身分

- ・ 査読者は名前と所属を 提供する義務がある
- 査読者は利害相反を明確にする義務がある



公開された査読の報告書

- ・ 査読者の報告書は論文と共 に公表される
- 引用可能且つレビューのメ トリクスがある



公開された査読状況

✓ APPROVED

The paper is scientifically sound in its current form and only minor, if any, improvements are suggested

? APPROVED WITH RESERVATIONS

A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.

★ NOT APPROVED

Fundamental flaws in the paper seriously undermine the findings and conclusions

査読者の知名度増加とクレジット

- 共同の査読
- ORCID ids
- 報告書のためのDOI付与



公開査読



- 1. F1000では、基本的には著者の推薦した5名以上の査読者とF1000のアルゴリズムの組み合わせにより、適切な資格を持つ査読者を招待します。
- 2. 出版前チェックを通過し論文が決定すると、少なくとも5名の査読者候補)の名前と連絡先 を教えてもらいます。査読者は著者とCOI(Conflict of Interest)利益相反がないこと。<u>同じ</u> 機関の研究者は査読者として推薦できません。F1000では利益相反をスクリーニングします。
- 3. 査読者のORCID IDが公開されます。査読者の仕事は査読者のORCID IDを通じてその研究に 貢献したことを認められ可視化されます。また、共同査読も推奨されています。

→ 査読者評価の仕組み → 若手研究者が初めて査読にチャレンジできる仕組み



著者が知っておくべき事項



査読者は著者とCOI(Conflict of Interest)利益相反がないことが前提です。同じ機関の研究者は査読者として推薦できません。F1000では利益相反をスクリーニングします。査読プロセスは完全に透明化されており、問題や不正が起きたときにすぐに分かるようになっています。

<u> 査読プロセスのいかなる時点でも、査読者に連絡することはご遠慮ください。</u>

著者と査読者の間のコミュニケーションは、査読報告書とコメント欄のみとしオープンで透明性のあるものにします。公開査読が行われているからといって審査中に審査について査読者に連絡を取ることは許されません。

著者主導で査読者を提案することができるのは、このような公開査読を行い不正を抑制しているともいえるからです。問題があった場合は、公開されている査読情報からどの段階で何が起こったかを検証することが可能です。この分野で発表している他の研究者は誰か、専門知識をもっている研究者は誰か(例えば同分野のConferenceのスピーカー、他誌、JIGの同分野・多機関所属の論文掲載者など)、研究にとって有用な査読者は誰なのか、事前に検討すると便利です。F1000は査読者の提案が適切かどうかをチェックし、論文の査読レポートが適切か出版前に確認をします。



JIGの査読者資格とは?



査読者は通常、博士号 (PhD/MD/MBBSまたはそれに相当するもの)を取得している必要があります。 専門家であること。査読者は、 関連するテーマについて少な くとも3本の論文を主著者とし て発表しており、少なくとも1 本は過去5年以内に発表したも のでなければなりません。

査読者は、論文の評価に偏り を生じさせるような利害関係 を有してはなりません。

F1000のどの論文でも、査読者は異なる機関の出身者であることを要求しています。

<u>同じ機関の研究者は査読でき</u> <u>ません。</u> 同じ国から複数の査読者の提案を受けた場合、編集部が一度に招待できるのは、そのうちの一人です。

(日本語論文は適用外)



公開査読 実際の画面表示

Export

Track

Email

Share





Alongside their report, reviewers assign **Open Peer Review** a status to the article:

Invited Reviewers

read

read

read

read

read

Institute, Phoenix, USA

Sud-Est. Marseille. France

Marseille, France

read

Richard Dortch (i), Barrow Neurological

Olivier Girard (b), Aix-Marseille University,

Lucas Soustelle (i), Aix-Marseille Univ, CNRS, CRMBM UMR 7339, Marseille, France; SATT

Douglas Dean (i), University of Wisconsin-

Wisconsin-Madison, Madison, USA; University

Madison, Madison, USA; University of

of Wisconsin-Madison, Madison, USA Gunther Helms (i), Lund University, Lund,

APPROVED

The paper is scientifically sound in its current form and only minor, if any, improvements are suggested

APPROVED WITH RESERVATIONS

Key revisions are required to address specific details and make the paper fully scientifically sound

X NOT APPROVED

Fundamental flaws in the paper seriously undermine the findings and conclusions

Visibility & credit for reviewers:

- Co-reviewing
- **ORCID** ids
- DOIs for reports

previous study in a single subject suggests this as a potential confound. Results: We demonstrated that ihMT ratios comparable to existing, acoustically loud,

Echo sequences which are among the most acoustically noisy MRI sequences, reducing patient

comfort during acquisition. We sought to address this by modifying a near silent MRI sequence to

Methods: A Magnetization Transfer preparation module was incorporated into a radial Zero Echo-

healthy subjects. We also investigated how head orientation affects ihMT across subjects, as a

Time sequence. Repeatability of the ihMT ratio and inverse ihMT ratio were assessed in a cohort of

implementations could be obtained with the silent sequence. We observed a small but significant effect of head orientation on inverse ihMTR.

Conclusions: Silent ihMT imaging is a comparable alternative to conventional, noisy, alternatives. For all future ihMT studies we recommend careful positioning of the subject within the scanner.

Keywords

include ihMT contrast.

オープンデータ Open Data





Open Dataのメリット



- ✓ 信頼性の向上:研究が再現可能であり検証可能であること
- ✓ 研究成果の認知度向上:論文とデータセットの両方が他の人に発見される仕組み→不正防止と科学の健全性の確保
- ✓ 研究者のキャリアに与える影響:オープンデータの共有は発表した 論文の引用回数を最大25%増加させるという統計があります *(Colavizza et al., https://doi.org/10.1371/journal.pone.0230416)

Five selfish reasons to work reproducibly

Florian Markowetz [™]





何を研究データとするか



研究の基礎となるデータをオープンに公開し世界に共有することが重要ですが、研究データが実際に何を意味するのか共通認識を持つことが重要です。

「研究データ」は、研究デザイン(研究設計)に応じて研究プロセスのINPUTまたはOUTPUTのいずれかになるでしょう。しかしデータの形式は分野によっても異なります。研究デザインと研究分野の違い次第で色々なデータがあるでしょう。













スプレッドシートのデータセットはかなり一般的ですが データは画像、ビデオ、音声記録などの形式をとることもある







FAIR原則推奨事項はすべて、F1000データガイドラインで提供されているガイダン スと一致しているため、F1000のガイドラインに従えばデータを国際基準でFAIR原 則にのっとり適切に公開することが可能

- ✓ Findable: データが検索可能。データ利用可能宣言に永続的な識別子 (DOIやURL)を含め データリポジトリに論文を紐づけ(リンク)
- ✓ Accessible: ウェブ上でアクセス可能な推奨データリポジトリを使用。
- ✓ Interoperable: 相互運用可能。専門分野で一般的な報告基準、ボキャブラリーを使用する。
- ✓ Reusable: 再利用可能。(データの標準ライセンスを含む)







Data Availability Statement (データ利用可能宣言と訳させて頂きます) は何より重要。 この宣言がないと論文は受理されたり出版されることはありません。

原稿の必須項目研究の基礎となるすべてのデータとその所在を記述する必要があります、 データのライセンス詳細も記載。

Data availability

Underlying data

Figshare: Underlying data for 'Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non- ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia'. https://doi.org/10.6084/m9.figshare.14673060.

The project contains the following underlying data:

- · Hema_Coagul_parameter_COVID.xlsx (main data).
- · readme.docx (index).

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

- リクエストに応じてデータを 開示できるようにするオプ ションはありません。
- 論文に関連するデータがない場合にも必要です(この場合、ステートメントは「No data are associated with this article」と表示されます)。



レポジトリにデータを保存



安定した認知度の高いオープンリポジトリにデータを預けること (推奨レポジトリリストがあり、F1000 Editorがレポジトリ選択 についてアドバイスが可能です。)

- レポジトリとはデータを保存しアクセスするためのウェブ上の場所です。
- ・ データの再利用を可能にするためにデータの文脈情報も提供することが可能です。
- 永続的な識別子(DOIなど)を提供しデータを引用できるようにします。
- 誰でもデータにアクセスすることが可能です!





zenodo





F1000 推奨レポジトリリスト



https://f1000research.com/gateways/japan-institutional-gateway/for-authors/data-guidelines https://f1000research.com/for-authors/data-guidelines#generaldata

What type of data	Which repository
Any	Dryad
Any, but especially data in SAV and POR formats	Dataverse
Any	Figshare
Any, but especially deposits with mixed data and code	Zenodo

Dryad、Dataverse、 Figshare、Zenodoには どのような研究データでも投 稿できます。

DataverseとZenodoはそれ ぞれSAVとPOR形式のデータ、 データとコードの混在した データに有利なようです。







研究結果の根拠(裏付け)となるデータ。

生データ (raw)や基礎データ(source)データ。

生データ・Raw data	ソースデータ・Source data
著者が研究で収集したすべての OUTPUTデータ。	著者らが研究で分析したすべての INPUTデータ。
例:ウェスタンブロット(切り抜き)、調査結果、配列、トランスクリプト、スペクトル	例:他の研究者から使用されたデータセット、人口統計学的な健康調査データ。
著者はこれを <u>データリポジトリに</u> アップロードする必要があります。	著者は、 <u>このソースデータをどこで</u> <u>入手したか</u> についての情報を提供し なければならない。



Extended Data 関連データ



Supplementary materialのような補足資料に相当するデータ。

Extended data

例:アンケート、同意書、統計解析の計算。

著者はこの情報を共有するかを選択できます。 <u>結果の再現性に影響を与えない資料であれば</u>、提供する必要は必 ずしもありません。

著者はこれらをデータリポジトリにアップロードする必要があり ます。



Data Availability宣言



データ利用可能宣言

ディスカッション/結論の Acknowledgementsの前に 記載してください

データがない場合もその旨、 宣言する必要がある

Conclusion

In this review of breastfeeding assessment tools for resource poor settings and targeting the assessment of malnourished infants less than 6 months, we have identified many possible but few stand-out 'gold standard' options. This represents an important evidence gap and highlights an urgent need for future research. The many different tools that we did find arguably show that one tool alone is unlikely to be suitable or even desirable. Tools must strike the right balance between simplicity, feasibility of use and minimal training requirements without losing the depth of information required to help healthcare workers and the women they are working with address breastfeeding difficulties. Thus, different tools for different levels of the health care system are needed; simple, quick-to-use tools for initial triage and problem identification in the community; more sophisticated tools for use in secondary and tertiary care settings where initial attempts at support have failed. Supplementary items such as pictures of good latch, and materials to help mothers and health workers understand the nature of breastfeeding problems (e.g. 'take action cards' (Dongre et al., 2010)), may be helpful. For any tool at any level, it is important that it leads to clear corrective actions. A "diagnosis" or "problem label" by itself is not always useful. Hence, future tools might give appropriate weight to problems, which can most readily be solved, or those which have the biggest short and long term impact. Research on breastfeeding assessment tools needs to consider such impacts - again, good test inter- and intra-observer validity is necessary but not alone sufficient to make a 'good' tool. It must help improve key outcomes like breastfeeding status and infant growth. Robustly designed studies in the contexts in which they will be used are essential.

Data availability

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Extended data

LSHTM Data Compass: Breastfeeding assessment tools for at-risk and malnourished infants aged under 6 months old: a systematic review, https://doi.org/10.17037/DATA.00001881 (Kerac et al., 2020).

This project contains the following extended data:

- Tools excluded from the second stage of the literature search
- Full search strategy

Reporting guidelines

LSHTM Data Compass: PRISMA checklist for 'Breastfeeding assessment tools for at-risk and malnourished infants aged under 6 months old: a systematic review', https://doi.org/10.17037/DATA.00001881 (Kerac et al., 2020).

Data are available under the terms of the Creative Commons Attribution-NonCommercial 2.0 UK license (CC BY-NC 2.0 UK).



免除と例外



データの作成・利用を行わなかった著者

倫理的またはセキュリティ上の理由で共有できないデータ(例: 研究参加者のプライバシーを保護するためなど)

データセットが大きすぎて、リポジトリにアップロードできない。

第三者が所有し、著者が再利用したデータ

この場合も、著者はデータをオープンに共有していない理由を説明するデータ利用可能性ステートメントを 提供する必要があります。



データデザイン・計画は研究を始める時に行うのがよい













プラン (計画)

- Data management plan
- Repository selection

準備

- Anonymise
- Create metadata (description)
- zCheck dataset, headers etc

デポジット

 Upload data to a repository and add metadata

宣言の記載

 Add a data availability statement to your manuscript

すべてのステップは、ジャーナルや出版プラットフォームに原稿を投稿する前に行うとよい